Role of mitochondrial fusion in doxorubicin-induced cardiotoxicity

Adriamycin is a widely used anti-tumor drug. Targeting mitochondrial fusion proteins/mitofusion 1/2(MFN1/2) and nuclear factor-erythroid 2-related factor 2(NRF2) can up-regulate the expression of mitochondrial fusion protein through PKCε/Stat3/MFN2, SIRT1/MFN2, AMPK/NRF2 and other signaling pathways, promote mitochondrial fusion, maintain kinetic balance and protect mitochondrial function, reduce myocardial cell apoptosis and reduce cardiac toxicity. Understanding the regulatory role and mechanism of mitochondrial fusion in doxorubicin-induced cardio toxicity will provide new strategies for the prevention and treatment of diseases.